Selvita (WAR:SLV) Stock Based Compensation: zł1.3 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:SLV Selvita SA WAR:SLV
80 GF Score
Price zł30.00
GF Value zł58.91
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Selvita Stock Based Compensation?

Selvita WAR:SLV 80 Stock Based Compensation is zł1.3 Mil as of Mar. 2026. GuruFocus rates WAR:SLV with a GF Score™ of 80/100 and a GF Value™ of zł58.91 (Significantly Undervalued). The stock has 4 warning signs investors should review.

Selvita's Stock Based Compensation for the three months ended in Mar. 2026 was zł0.1 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was zł1.3 Mil.

Selvita Stock Based Compensation Related Terms

Selvita Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Selvita's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Selvita Stock Based Compensation Chart

Selvita Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 31.47 30.84 11.51 3.19 1.94

Selvita Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.76 0.59 0.40 0.20 0.11
WAR:SLV
80GF Score
Selvita SA WAR:SLV
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Selvita Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł1.3 Mil.

What does a Stock Based Compensation of zł1.3 Mil mean?
Selvita (WAR:SLV) has a Stock Based Compensation of zł1.3 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Selvita and its competitors.
Is Selvita's Stock Based Compensation too high?
Selvita's current Stock Based Compensation is zł1.3 Mil. Overall, Selvita has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Selvita's Stock Based Compensation compare to TMO and DHR?
Selvita's Stock Based Compensation of zł1.3 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Medical Diagnostics & Research company?
A good Stock Based Compensation depends on the Medical Diagnostics & Research industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Selvita and its competitors. Selvita's current Stock Based Compensation is zł1.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Selvita stock overvalued right now?
Based on GuruFocus' analysis, Selvita (WAR:SLV) is currently considered Significantly Undervalued. The stock's GF Value™ is zł58.91, compared to a current price of zł30.00 — trading 49.1% below its estimated fair value. The current Stock Based Compensation is zł1.3 Mil. Selvita's overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Selvita (WAR:SLV), the current Stock Based Compensation is zł1.3 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Selvita (WAR:SLV) Overvalued in 2026?

Based on GuruFocus' analysis, Selvita stock appears to be undervalued. The current stock price of zł30.00 is trading 49.1% below its estimated GF Value™ of zł58.91. GuruFocus considers Selvita to be Significantly Undervalued.

Key valuation signals for WAR:SLV:

  • Stock Based Compensation: zł1.3 Mil
  • GF Value™: zł58.91 vs. price of zł30.00 (49.1% below fair value)
  • GF Score™: 80/100 with 4 warning signs

No single metric tells the full story. See the WAR:SLV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Selvita Business Description

Other Exchanges 787:Germany
Address Bobrzynskiego 14, Park Life Science, Krakow, POL, 30-348
Selvita SA is a Poland based parent company of Selvita Group is one of the largest preclinical contract research organizations in Europe. It also develops bioinformatics solutions supporting innovative projects at preclinical stages. It also provides services provided to external contractors are in the field of chemistry, analytics, regulatory, biochemistry and cell biology and also the integrated research and development projects.
80GF Score

Get the complete analysis for WAR:SLV

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł30.00
Price
zł58.91
GF Value